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Autoimmune disorders are characterized 
by an inappropriate, ultimately exces-
sive, inflammatory response against 
self, resulting in tissue destruction. 
Although many individuals affected by 
autoimmunity demonstrate multiorgan 
involvement, the primary end-organ 
target (e.g., autoimmune destruction of 
pancreatic islet cells in type 1 diabe-
tes mellitus) typically drives the clinical 
presentation and disease definition. 
Evidence for both B and T lymphocyte 
hyper-reactivity is typically observed, 
with the presence of autoantibodies 
and genetic associations involving 
the major histocompatibility complex 
(MHC) providing the most significant 
association evidence for many autoim-
mune diseases.
Most cases of autoimmunity arise in 
the absence of a positive family history. 
However, evidence that genetic factors 
contribute to disease pathogenesis has 
been provided by familial clustering 
in some cases, which reflects shared 
genetic, developmental, and environ-
mental factors. The contribution of 
genetic factors is established through 
twin studies demonstrating higher 
disease concordance in monozygotic 
compared to dizygotic twins. In con-
trast to single-gene, Mendelian disor-
ders, complex genetic disorders such 
as many autoimmune diseases are 
associated with multiple genetic loci, 
conferring varying effects on disease 
susceptibility.
Within families, clustering of distinct 
autoimmune diseases has been reported, 
and this suggests the presence of shared 
pathogenic factors across autoimmunity. 
For example, a large, population-based 
survey demonstrated that families with a 
rheumatoid arthritis (RA) (Lin et al., 1998) 
or multiple sclerosis (MS) (Broadley et al., 
2000) proband were more likely to also 
manifest other autoimmune disorders. 
Compared to families with a single mem-
ber affected by MS, the frequency of 
other autoimmune diseases was higher 
in families containing multiple members 
with MS, suggesting a cumulative enrich-
ment of autoimmune susceptibility loci in 
these select cohorts.
The application of genome-wide asso-
ciation studies (GWAS) to autoimmune 
diseases has identified a growing num-
ber of disease-associated loci. GWAS 
involve the genotyping of several hundred 
thousand single-nucleotide polymor-
phisms (SNPs) throughout the genome 
in large case-control cohorts (Manolio 
et al., 2009). Because of the large num-
ber of statistical tests applied, strin-
gent statistical thresholds are required 
(p value less than 5 × 10−8) to establish 
genome-wide evidence for association. 
For many associated loci, the associa-
tion signals do not directly implicate a 
single, protein-coding gene, and the 
causative role for candidate genes in 
the region can only be speculated. A 
striking number of major loci have been 
observed to demonstrate genome-wide 
evidence for association in multiple, 
distinct autoimmune disorders (Table 1) 
(Barrett et al., 2008, 2009; Festen et al., 
2009; Franke et al., 2008; Gateva et al., 
2009; Gregersen et al., 2009; Han et al., 
2009; Hom et al., 2008; Raychaudhuri et 
al., 2009; van Heel et al., 2007; WTCCC, 
2007; Zhernakova et al., 2007). Given 
the a priori epidemiological support for 
shared pathogenesis across autoim-
mune disorders, it may be argued that 
less stringent evidence for association 
would be required to establish contribu-
tions for those loci previously established 
in another, distinct autoimmune disease. 
Efforts to comprehensively genotype 
variation at all genome-wide significant 
autoimmune loci across all autoimmune 
diseases are ongoing. These studies will 
provide enormous insight into shared 
and distinct patterns of genetic associa-
tions across autoimmunity.
Notably, many inflammatory genes 
implicated in autoimmunity demonstrate 
broad expression patterns and pleio-
tropic functions. However, integrative 
themes are emerging, implicating both 
established and new mechanisms of 
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inflammation. Associated loci include 
a broad array of immune-associated 
genes involved in lymphocyte activa-
tion (receptor signaling pathways and 
costimulation), microbial recognition, 
and cytokines or cytokine receptors 
(Gregersen and Olsson, 2009). In the 
following sections, we highlight select 
genetic associations demonstrating the 
most significant evidence for associa-
tions in multiple autoimmune diseases.
Lymphocyte Activation in 
 Autoimmunity
For many autoimmune disorders, the 
MHC represents the predominant asso-
ciation, highlighting its central and com-
plex role in mediating host inflammatory 
responses to evolutionarily significant 
pathogens. The nature of antigenic 
responses to self- or non-self-antigens is 
shaped extensively by the unique coding 
and noncoding genetic variation of HLA 
alleles. Extensive allelic variation and link-
age disequilibrium (nonrandom or corre-
lated association of alleles) are observed 
throughout the MHC region. Recent high-
density mapping in multiple autoimmune 
diseases demonstrated complex, multilo-
cus effects that span the entire region, 
with evidence for shared and unique loci 
across diseases (Rioux et al., 2009).
After the MHC, one of the most com-
mon genetic associations across auto-
immune disorders is observed at the 
protein tyrosine phosphatase gene 
PTPN22, expressed in lymphocytes. The 
minor tryptophan allele at Arg620Trp 
within PTPN22 has been associated 
with numerous autoimmune diseases 
including type 1 diabetes mellitus, RA, 
autoimmune thyroiditis, and systemic 
lupus erythematosis (SLE) (Barrett et al., 
2008; Bottini et al., 2004, WTCCC, 2007; 
Criswell et al., 2005). Interestingly, the 
more common arginine allele is associ-
ated with an inflammatory bowel disor-
der called Crohn’s disease (Barrett et al., 
2008). The tryptophan allele results in a 
gain of function by the phosphatase pro-
tein relative to the arginine allele, such 
that B and T cell activation is inhibited; 
tryptophan homozygotes are character-
ized by a profound defect in lymphocyte 
receptor signaling (Rieck et al., 2007; 
Vang et al., 2005). It is possible that 
impaired T cell signaling increases auto-
immune susceptibility by contributing 
to a failure to delete autoreactive T cells 
during thymic selection, impaired activ-
ity of regulatory T cell populations (Vang 
et al., 2005), or defects in clearance of 
microbes, such as viruses.
The plethora of associated loci contain-
ing candidate genes encoding molecules 
expressed by lymphocytes that modulate 
costimulatory functions (e.g., CTLA-4, 
CD2/CD58, CD28, ICOSLG, TNFSF15) 
(Cooper et al., 2008; De Jager et al., 
2009; Gregersen et al., 2009; Gregersen 
and Olsson, 2009; Raychaudhuri et al., 
2009) further highlights the centrality of 
lymphocyte activation in human autoim-
munity. However, the nature (expression 
isoforms, cell-specific expression levels) 
of altered gene function resulting from 
disease-associated polymorphisms is 
largely undefined.
Cytokine Pathways
Numerous combinations of cytokines and 
cytokine receptors have been associated 
with autoimmunity, with common and 
distinct patterns of association evidence 
reported across disorders. For example, 
both type 1 diabetes mellitus and MS 
demonstrate association to interleukin 
2 receptor alpha (IL2RA), and MS also 
demonstrates association to interleukin 7 
receptor alpha (IL7R) (Barrett et al., 2009; 
Hafler et al., 2007). However, no evidence 
for association in either disease has been 
observed thus far for the shared inter-
leukin 2 receptor gamma chain (IL2RG) 
required for interleukin 7 and interleukin 
2 signaling. Although IL-7 has not been 
clearly associated with autoimmunity, 
associations in a gene region on chromo-
some 4q27 near the IL-2 and IL-21 genes 
have been reported in celiac disease, 
inflammatory bowel disease (IBD), RA, 
and type 1 diabetes (Barrett et al., 2009; 
Festen et al., 2009; van Heel et al., 2007; 
Zhernakova et al., 2007), but not thus far 
in MS (Table 1).
A more consistent example of 
cytokine-cytokine receptor involvement 
is provided by the IL-12/IL-23 pathway 
in IBD, ankylosing spondylitis, and pso-
riasis (A.B. Begovich et al., 2006, Am. J. 
Hum. Genet. abstract; Burton et al., 2007; 
Duerr et al., 2006). Both IBD and psoria-
sis demonstrate association to the inter-
leukin 12 p40 subunit (IL12B) (Begovich 
Table 1. Association of Genomic Loci with Autoimmune Diseases
Chromosome  
Region
Genes of 
Interesta
Function Diseasesb
1p13 PTPN22 T and B cell receptor signaling RA, T1D, CD
2q33 CTLA4 Transmits inhibitory signals to T cells T1D, RA
6p21 MHC Major histocompatibility complex Most autoimmune 
disorders
1p13 CD2/CD58 Activation of T lymphocytes RA, MS
1p31 IL23R Unique component of the heterodimeric 
IL-23 receptor
IBD, PS, AS
1q32 IL10 Downregulates immune responses, includ-
ing cytokines, MHC class II and costimula-
tory molecules
IBD, SLE, T1D
4q26 IL2/IL21 T cell trophic growth factors CeD, IBD, RA, T1D
5q33 IL12B p40 subunit common to IL-12 and IL-23 IBD, PS
10p15 IL2RA IL-2 receptor α chain MS, T1D
6q23 TNFAIP3 Induced by TNF and pattern recognition 
receptor activation; inhibits NF-κB signaling
RA, SLE, PS
5q33 TNIP1 Interacts with TNFAIP3 SLE, PS
6q21 PRDM1 Transcriptional repressor of IFN-β; induces 
B cell maturation
RA, SLE
8p23 BLK B lymphoid tyrosine kinase SLE, RA
18p11 PTPN2 T cell protein tyrosine phosphatase IBD, T1D
Genome-wide significant association defined as p value < 5 × 10− 8.
aAssociation regions often encompass either no genes or multiple genes, with the precise causal 
gene often not definitively established.
bAS, ankylosing spondylitis; CeD, celiac disease; IBD, inflammatory bowel disease; MS, multiple 
sclerosis; PS, psoriasis; RA, rheumatoid arthritis; T1D, type 1 diabetes mellitus.
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et al., 2006; Nair et al., 2009), common 
to IL-12 and IL-23 cytokines, as well as to 
the interleukin 23 receptor (IL23R), which 
represents the IL-23-specific component 
of the heterodimeric cytokine receptor. 
The interleukin 23 pathway plays a cen-
tral role in antimicrobial defenses and 
mucosal immunity, in part through expan-
sion of Th17 lymphocytes. However, the 
role of Th17-lineage cytokines in the tis-
sues associated with these respective 
diseases can lead to distinct outcomes. 
Recent data have shown that IL-23 medi-
ates dermal inflammation through the 
Th17 cytokine IL-22 (Zheng et al., 2007). 
IL-22 stimulation of keratinocytes leads 
to hyperplasia of keratinocyte layers and 
induction of expression of antimicrobial 
peptides such as β-defensin (Zenewicz 
and Flavell, 2008). On the other hand, 
experimental mouse models of IBD sug-
gest that IL-22 is protective in the intes-
tine (Sugimoto et al., 2008; Zenewicz et 
al., 2008). IL-22 stimulation of colonic 
epithelial cells may help to maintain the 
barrier function of the intestine, as well 
as induce expression of antimicrobial 
peptides and mucins. The dual nature of 
this cytokine, protective versus inflam-
matory, likely depends on the inflam-
matory context and tissues involved. In 
addition to cytokine-cytokine receptor 
associations, IBD associations implicate 
downstream members of the interleukin 
23 pathway including Janus-activated 
kinase 2 (JAK2) and signal transducer 
and activator of transcription 3 (STAT3) 
(Abraham and Cho, 2009).
The tumor necrosis factor (TNF) path-
way represents a central therapeutic tar-
get across many autoimmune diseases. 
Multiple downstream components of 
TNF signaling have been associated in 
autoimmunity, most notably the tumor 
necrosis factor-inducible protein A20 
(TNFAIP3), which terminates TNF- and 
pattern recognition receptor-induced 
responses of the transcription factor 
NF-κB. The gene region near TNFAIP3 
has been associated with SLE, psoria-
sis, and RA (Nair et al., 2009; Plenge et 
al., 2007a; Thomson et al., 2007). In addi-
tion, TNIP1 (TNFAIP3-interacting protein 
1), which interacts with TNFAIP3, is also 
associated with psoriasis and SLE (Han 
et al., 2009; Nair et al., 2009). Addi-
tional downstream components of TNF 
signaling have associations to RA, for 
example, TNF receptor-associated fac-
tor 1 (TRAF1) (Plenge et al., 2007b) and 
Rel, a component of NF-κB signaling 
(Gregersen et al., 2009).
Microbial Responses
Although genetic variants altering lym-
phocyte activation and cytokine sig-
naling modulate microbial responses, 
more specific examples of host genetic 
variation provide additional insight into 
mechanisms of autoimmunity. The com-
plex relationships between viral infec-
tion and autoimmunity are highlighted 
through associations in genes encod-
ing interferon regulatory factor 5 (IRF5) 
and interferon induced with helicase C 
domain 1 (IFIH1). The IRF5 gene has 
been associated with SLE (Graham et 
al., 2006), with some evidence for asso-
ciation to other autoimmune diseases. 
IRF5 is downstream of pattern recog-
nition receptor signaling and induces 
numerous cytokines, including type 1 
interferons. The SLE-associated IRF5 
association signals are complex, with 
some polymorphisms characterized 
by increased expression of IRF5 iso-
forms (Graham et al., 2006). Microarray 
studies of peripheral blood from SLE 
patients have demonstrated a strong 
type 1 interferon signature (Pascual et 
al., 2006).
More recently, uncommon polymor-
phisms in IFIH1, including a nonsense 
mutation, have been demonstrated to 
confer protection against developing 
type 1 diabetes mellitus (Nejentsev et 
al., 2009). IFIH1 recognizes RNA from 
picornaviruses and mediates immune 
activation. Importantly, infections with 
enteroviruses, members of the picorna-
virus family, are more frequent in newly 
diagnosed cases of type 1 diabetes 
mellitus and antedate the onset of dis-
ease-associated autoantibodies. Future 
studies testing whether wild-type IFIH1-
mediated immune responses to entero-
viruses induce autoreactive lymphocytes 
will provide key insight into its role in dis-
ease pathogenesis.
If the IRF5 and IFIH1 associations 
highlight pathogenic roles of increased 
and wild-type host microbial responses, 
respectively, equally important is the 
concept that impaired, initial microbial 
responses may also result ultimately 
in increased inflammation. IBD is com-
prised of two major subtypes, Crohn’s 
disease and ulcerative colitis. Both sub-
types are associated with multiple IL-23 
pathway genes. However, only Crohn’s 
disease is associated with loss-of-func-
tion polymorphisms in NOD2 (pattern 
recognition receptor for bacterial pep-
tidoglycan, normally resulting in NF-κB 
activation) and in ATG16L1-mediated 
autophagy. IBD is believed to result from 
an inappropriate host response to com-
mensal intestinal microbes, resulting ulti-
mately in intestinal damage from exces-
sive inflammation (Abraham and Cho, 
2009). There is a functional link between 
pattern recognition receptors, including 
Table 2. Emerging Approaches and Potential Advances
Approach Established and Potential Advances
Genome-wide association studies Have identified a large number of definitive associations across autoimmunity, with many 
shared across autoimmune diseases
Search for uncommon DNA variants May identify more penetrant alleles with larger functional effects
Transcriptome sequencing Will identify tissue-specific alternative isoforms, noncoding RNAs
Expression quantitative trait loci mapping Mapping DNA polymorphisms to variable RNA expression
Epigenetic analysis: chromatin modifications More comprehensive maps of DNA sequences modulating transcriptional regulation
Sequence analysis of the intestinal microbiome Potentially tractable environment covariate modulating intestinal and systemic immune 
responses
Humanized mice Incorporates key human immune response components in model systems
Human immune analyses Prioritize new therapies, identify disease subtypes, and follow disease course
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NOD2 and ATG16L1 (Cooney et al., 2009; 
Travassos et al., 2009). In addition, both 
NOD2 and ATG16L1 are expressed in a 
variety of innate cells, lymphocytes, and 
gut epithelial Paneth cells, which secrete 
potent antimicrobial peptides (Abraham 
and Cho, 2009). Therefore, in Crohn’s 
disease, defects in first line mucosal 
clearance of microbes may ultimately 
contribute to excessive chronic inflam-
matory responses.
Beyond GWAS: Assessment and 
Challenges
Current GWAS have sampled common 
variation throughout the genome for 
disease associations (Table 2). Newer 
genotyping platforms that more com-
prehensively assay common variation 
will likely identify important new disease 
associations. GWAS in non-European 
populations provide important compara-
tive insight. In addition, combining larger 
case-control cohorts will likely identify 
genomic loci of modest effect, for which 
smaller studies were underpowered. 
Identification of additional genes will 
provide cumulative insight into disease 
pathways and complex functional net-
works. However, for all of these com-
plex autoimmune disorders, presently 
identified loci account for only a minor 
fraction of the predicted heritability. The 
identification of additional loci requiring 
ever larger meta-analysis cohorts using 
similar methodology will likely not have 
a significant impact on accounting for 
overall heritability. This would indicate 
that genetic variation that is not well 
assayed through present approaches 
may yet provide a significant contribu-
tion to overall disease heritability (Clay-
ton, 2009; Manolio et al., 2009).
More comprehensive cataloguing of 
genetic variation is ongoing, acceler-
ated significantly by high-throughput 
sequencing technologies. Uncommon 
SNPs, and other not well assayed genetic 
variations, may provide significant addi-
tional sources of disease-associated 
genetic variation. Equally important, 
these sequencing technologies are pro-
viding data on tissue-specific transcrip-
tome expression and epigenetic regula-
tion, which may be particularly relevant 
to autoimmune diseases. Given the cen-
tral role of host-microbe interactions, 
sequence-based analyses of microbial 
communities will also provide impor-
tant insight. The plethora of data that 
will be generated through these emerg-
ing approaches presents challenges 
and opportunities to define the under-
lying rules governing immune system 
responses and perturbations resulting in 
autoimmunity.
Beyond GWAS: Uncommon and 
Non-SNP-Based Variation
In many cases, the association signals 
identified by GWAS will be largely driven 
by relatively common genetic variation 
of modest effect, with increased risks of 
1.1 to 1.5 per associated allele typically 
observed (Altshuler et al., 2008). How-
ever, functional genetic variation having 
a greater effect on disease susceptibil-
ity would be maintained at relatively low 
frequencies within populations due to 
purifying selection. It is anticipated that 
uncommon genetic variation, in the form 
of SNPs, copy number polymorphisms, 
and other insertions/deletions through-
out the genome, may contribute sig-
nificantly to the genetics of autoimmune 
diseases. A comprehensive cataloguing 
of these less common variants is being 
completed through the 1000 Genomes 
Project (http://www.1000genomes.org). 
By definition, identifying less common 
genetic variation will require deeper inter-
rogation of larger sequencing cohorts 
from diverse populations.
There are both practical and meth-
odological challenges to establishing 
disease associations for uncommon 
alleles. Practical considerations include 
increased technical difficulties associ-
ated with definitively establishing and 
validating the presence of uncommon 
alleles. In addition, there is the potential 
for less accurate genotype assignments, 
which are often based on clustering 
algorithms. Methodological challenges 
include the decreased power to estab-
lish disease associations for uncommon 
alleles compared to common alleles. The 
plethora of independent, uncommon 
variants compared with the more limited 
subset of common variants increases 
the potential number of statistical tests 
applied in a comprehensive genotyp-
ing approach for uncommon variants. 
Because of these factors, more intensive 
surveys for uncommon variation have 
focused on protein-coding genes (Ng et 
al., 2009) and developing gene-based 
tests of association that incorporate 
multiple uncommon alleles simultane-
ously. With the advent of whole-genome, 
exon-capture techniques followed by 
high-throughput sequencing, studies 
testing for association to uncommon, 
coding region variants have now been 
reported (Choi et al., 2009).
Identifying Functional Variation 
within Disease-Associated Loci
The presence of only one gene within an 
association signal typically implicates it 
in disease pathogenesis, with the strong 
caveat that functional proof of disease 
causation will typically not be estab-
lished for complex disease gene asso-
ciations. As opposed to Mendelian dis-
eases, in complex, multigenic diseases, 
single-gene alterations by themselves are 
insufficient to drive disease expression. 
Because of the highly correlated nature of 
common variants in the human genome, 
association signals often encompass 
multiple, protein-coding genes demon-
strating equivalent statistical evidence for 
association. In these cases, dissection 
of which gene is generating the associa-
tion signal may be difficult to establish. 
At the other end of the spectrum, many 
GWAS-identified association signals are 
confined to gene deserts containing no 
protein-coding genes.
Disease-associated missense muta-
tions at conserved amino acid residues 
represent strong candidates meriting fur-
ther functional analyses. In many cases, 
however, functional variants may exert 
their major effects through more subtle 
regulatory effects on gene expression. 
Genome-wide linkage and association 
studies mapping DNA variation with vari-
able mRNA expression through expres-
sion quantitative trait loci (eQTL) map-
ping have generated a rich source of 
likely functional polymorphisms (Dixon 
et al., 2007). However, these studies 
do not generally confirm that the DNA 
polymorphisms regulate variable pro-
tein expression, and posttranscriptional 
mechanisms of gene regulation have 
not been comprehensively evaluated. 
Equally important, eQTL studies con-
fined to a single cell type likely represent 
only a subset of DNA polymorphisms 
regulating gene expression. In this 
regard, studies utilizing primary human 
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cells or relevant tissues (Emilsson et al., 
2008) to map DNA variation with vari-
able RNA expression may be particularly 
useful in autoimmune diseases. These 
approaches have now been applied to 
various diseases. For example, a study 
using primary human peripheral blood 
mononuclear cells demonstrated that 
a DNA haplotype in a region including 
IL2RA (CD25) that confers protection 
against type 1 diabetes mellitus and 
MS is associated with increased CD25 
expression in CD4+ memory T cells. Key 
to the successful completion of such 
well-powered studies is the availability 
of large bioresources of healthy controls 
that allow for efficient recall of individu-
als stratified on genotypes of interest 
(Dendrou et al., 2009).
Much of the impetus toward defining 
functional consequences of disease-
associated polymorphisms has focused 
on protein-coding genes. However, 
although protein-coding genes repre-
sent a small minority of the genome, it is 
important to note that the majority of the 
genome is actively transcribed, resulting 
in a complex network of short and long 
noncoding RNAs that have complex, 
and currently incompletely understood, 
effects on gene regulation and cellular 
function (Encode Project Consortium, 
2007). The pervasiveness of these non-
coding RNAs would suggest that at least 
some of the association signals pres-
ently observed in “gene deserts,” as well 
as within regions containing the more 
familiar protein-coding genes, may be 
driven by altered functional effects of 
noncoding RNAs.
Developing Predictive Disease 
Models
Establishing a more complete catalog 
of common and uncommon genetic 
associations, as well as more precisely 
defining the functional variation at each 
associated locus, represent important, 
intermediate goals in the genetics of 
autoimmunity. However, a major goal 
moving forward is the development of 
improved predictive models for disease. 
Such models, applied to both human dis-
ease and model systems, ideally would 
encompass an improved capacity to 
predict disease risk and model disease 
progression, improved disease classi-
fication across and within autoimmune 
diseases based on pathophysiological 
mechanisms, and improved prediction of 
therapeutic responses, both in the devel-
opment of new therapeutic agents and in 
the application to individual patients. The 
rapid advances and decreasing costs of 
high-throughput sequencing approaches 
provide a powerful tool to address some 
of these challenges. Applying recent high-
throughput sequencing technologies to 
classic genetic approaches of examining 
phenotypic extremes, early onset cases, 
and twin studies may provide important 
insight. Although the significance of GWAS 
rests with definitive DNA-to-disease 
mappings, defining intermediate map-
pings between DNA sequence, chromatin 
modifications, and RNA expression will 
provide insight into molecular networks 
and predictive behavior that may form the 
basis for more rational therapeutic devel-
opment (Schadt, 2009). For example, twin 
studies provide an important means of 
examining the interplay between genetic, 
environmental, and development factors 
contributing to autoimmunity.
Twin Studies in Genetics and 
Autoimmunity
The finding of significantly higher 
monozygotic compared to dizygotic 
twin concordance for a given disease is 
used as proof that genetic factors play a 
significant role in disease pathogenesis, 
and that genetic mapping studies are 
merited. Twin concordance studies form 
a basis for composite disease heritabil-
ity estimates. However, the composite 
cohort of twin pairs for a given disease 
encompasses a wide range of genetic 
backgrounds, with likely very different 
genetic propensities for disease and 
subphenotype expression.
Perhaps one of the more tractable 
environmental covariates modulating 
autoimmune disease involves the bidi-
rectional crosstalk between the host and 
intestinal microbiomes. A recent study 
demonstrated that the human gut micro-
biome demonstrates familial similarity, 
with comparable degrees of covariance 
between adult dizygotic and monozy-
gotic twins; a nonsignificant trend toward 
increased similarity between monozy-
gotic twin pairs was observed (Turn-
baugh et al., 2009). However, a clear role 
for host genetic background in altering 
distal gut microbiome composition was 
demonstrated in MyD88-deficient mice 
compared to their littermate controls, 
with an altered propensity to develop 
autoimmune diabetes (Wen et al., 2008).
Developmental factors also signifi-
cantly modulate gene expression; this 
is clearly illustrated in twin studies com-
paring methylation status assessed by 
microarray analysis of CpG islands. 
Overall, monozygotic twin correlation of 
methylation status was higher than that 
observed in dizygotic twins. However, 
within monozygotic twins, correlations 
were lower for dichorionic compared 
to monochorionic monozygotic twins, 
indicating that factors other than DNA 
sequence modulate epigenetic regula-
tion (Kaminsky et al., 2009). The poten-
tial contribution of the underlying DNA 
sequence in chromatin modification can 
be systematically defined through chro-
matin immunoprecipitation (ChIP-seq) or 
through formaldehyde-assisted isolation 
of regulatory elements (FAIRE-seq), fol-
lowed by high-throughput sequencing. 
Although extensive work has focused 
on epigenetic alterations in neoplasia, 
the development of genome-wide maps 
of chromatin states in pluripotent and 
lineage-committed cells can now be 
applied to the genetics and genomics of 
autoimmunity (Meissner et al., 2008).
Epigenetics in Autoimmunity
Genome-wide maps of epigenetic regu-
lation will provide enormous amounts of 
information, along with the challenge of 
defining the underlying rules that govern 
gene expression and cellular differen-
tiation. For example, key transcription 
factors and lineage-specific cytokines 
in CD4+ T cell subsets demonstrate a 
broad spectrum of epigenetic states, 
contributing to a useful framework for 
understanding specificity and plasticity 
of CD4+ T cell subsets. H3K4me3 and 
H3K27me3 histone modifications are 
enriched in active and inactive chroma-
tin regions, respectively, and effectively 
discriminate between genes that are 
expressed, poised for expression, or 
stably repressed (Meissner et al., 2008). 
An improved understanding of epigenet-
ics and autoimmune diseases will likely 
provide insight into the pathophysiology 
of specific autoimmune diseases and 
may assist in improved diagnosis and 
treatment.
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Model Development in Autoimmunity
The application of genetic and genomic 
approaches to build useful predictive 
models of autoimmune disease ideally 
would encompass development of murine 
models of disease that integrate primary 
factors in human disease pathogenesis 
and predict therapeutic responses in 
humans. Predictive models in humans 
ideally would include defining individu-
als at risk for disease development, as 
well as predicting disease prognosis 
and informing therapeutic management. 
The continuum between monogenic and 
polygenic human diseases illustrates the 
challenges and opportunities. For exam-
ple, the identification of rare Mendelian 
autoimmune disorders in humans (e.g., 
mutations in AIRE; Mathis and Benoist, 
2009) has provided enormous insight 
into basic mechanisms of autoimmu-
nity, enhanced by similar phenotypic 
manifestations in corresponding murine 
genetic models. Conversely, the devel-
opment of single-gene, murine models of 
disease has provided significant insight; 
the identification of correlative disease 
associations in a given gene through 
GWAS in humans would prioritize that 
gene and pathway as playing a more sig-
nificant role in human disease. However, 
complete knockdown of single-gene 
expression in murine models will result 
in very different downstream conse-
quences compared to the more subtle 
effects on gene function resulting from 
the human SNP associations that have 
typically been identified through GWAS. 
Reporter constructs tagging immune cell 
subsets integrated with single-gene and 
spontaneous autoimmune disease mod-
els provide important refinement of the 
ability to study key immune cell subsets. 
For example, a double-transgenic mouse 
model distinguishing T cells expressing 
FoxP3+ and “exFoxP3” established that 
the exFoxP3 subset of cells express-
ing both IL-17 and IFN-γ led to the rapid 
development of diabetes, underscor-
ing the potential significance of cellular 
plasticity in autoimmunity (Zhou et al., 
2009).
More broadly, modeling complex 
autoimmune diseases in mice has 
limitations due to inherent differences 
between the murine and human immune 
systems (Mestas and Hughes, 2004). To 
better recapitulate the human immune 
response, researchers have devel-
oped “humanized” mice. Humanized 
mice encompass two distinct models: 
(1) transgenic mice expressing human 
genes and (2) immunodeficient mice 
engrafted with human peripheral blood 
mononuclear cells or hematopoietic 
cells to generate a “human” immune 
system. These systems, alone or com-
bined together, allow us to model human 
immune responses within the confines 
of mice, with all of their research advan-
tages. The optimization of engraftment of 
human stem cells into immunodeficient 
mice is an area of active research. Mice 
expressing human cytokines or cytokine 
receptors will be potentially superior 
hosts for more closely understanding the 
development and activation of human 
immune responses in vivo (Huntington et 
al., 2009). Preclinical studies testing new 
therapies in increasingly refined murine 
models of autoimmunity may enhance 
predictive capacity for new treatments in 
human disease.
Human Studies of Autoimmunity
Ultimately, methodologies to improve 
human studies, in parallel with refined 
model systems, will be required for 
future advances. Recent genetic associ-
ation studies have prioritized shared and 
unique mechanisms of lymphocyte acti-
vation and cytokine signaling between 
various autoimmune disorders. Com-
parative studies between various auto-
immune disorders, integrating genetic 
and expression data, as well as immune 
system function, will be important in pri-
oritizing new therapeutic approaches, 
categorizing diseases into subsets and 
delineating individuals with distinct 
immune system functions, and modulat-
ing inflammatory responses with thera-
peutic interventions.
Clinical applications of expression 
analyses have been very successfully 
applied to some autoimmune disor-
ders, notably SLE. SLE affects many 
different organs, including the heart, 
kidneys, skin, joints, and nervous sys-
tem (Rahman and Isenberg, 2008), and 
the disease course is often unpredict-
able. Due to the heterogeneity of SLE, 
the use of biomarker signatures for the 
diagnosis and tracking of disease pro-
gression would be a valuable tool. Mod-
ular analysis, in which transcription of a 
group of genes is assessed, has recently 
been applied to SLE (Chaussabel et al., 
2008). SLE patient transcriptional pro-
files were followed over time and found 
to correlate with disease activity. These 
transcriptional analyses have been 
applied to diagnosis, monitoring of the 
disease course, and therapeutic inter-
ventions. It may be argued that periph-
eral blood immune system responses 
may not reflect relevant, organ-specific 
immune responses; the success of these 
approaches in SLE may reflect its sys-
temic nature. However, alterations in 
systemic immune system function have 
been identified across autoimmune dis-
eases, and similar approaches in other 
autoimmune disorders will likely identify 
important comparative insight. More gen-
erally, the development of innovative and 
uniform methods for immune monitoring 
in health and disease and in the context 
of clinical trials represents an extremely 
high priority. Given the extensive genetic, 
functional, and therapeutic overlap 
between various autoimmune disorders, 
it is anticipated that the most rapid and 
significant advances will be attained 
through comparative approaches. The 
mosaic of disease-associated autoim-
mune loci identified by GWAS highlights 
key functional polymorphisms, which 
together with developmental and envi-
ronmental factors result in an increased 
propensity for developing inflammatory 
disease in humans.
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